化合物详情
CAS13327-32-7
分子式BeH2O2
分子量43.03 g/mol
危化品
Beryllium dihydroxide is a beryllium hydroxide.
科学粮草官-词典编辑部,修订于:2026-07-06

Toxicity
ToxicityFate Summary
AQUATIC FATE: In aqueous solution, beryllium exhibits only the +2 oxidation state(1). Soluble beryllium salts are hydrolyzed to form insoluble beryllium hydroxides(2). Under typical environmental conditions, the hydroxo-complex BeOH+ and Be2+, are expected to be the dominant dissolved species(1). Be(OH)2 is expected to precipitate from water given its low solubility at the pH range of most natural systems(1).
Environmental Water Concentrations
Beryllium is not likely to be found in natural water in greater than trace amt, because of the relative insolubility of beryllium oxides & hydroxides @ normal ph range of such water.
Probable Routes of Human Exposure
According to the 2006 TSCA Inventory Update Reporting data, the number of persons reasonably likely to be exposed in the industrial manufacturing, processing, and use of beryllium hydroxide is 1 to 99; the data may be greatly underestimated(1).
Symptoms
Chronic beryllium disease causes fatigue, weakness, difficulty breathing, and a persistent dry cough. (L24, L25)
Treatment
Chronic beryllium disease is treated with immunosuppressive medicines, usually of the glucocorticoid class. (L24)
Health Effects
Acute inhalation of a high level of beryllium can results in a pneumonia-like condition called acute beryllium disease. Chronic inhalation of beryllium can caused an inflammatory reaction in the respiratory system called chronic beryllium disease. Chronic beryllium disease may result in anorexia and weight loss, as well as right side heart enlargement and heart disease in advanced cases. Chronic exposure can also increase the risk of lung cancer. Skin contact with beryllium results in contact dermatitus. (L24, L25)
Adverse Effects
Fibrogenic - Inducing tissue injury and fibrosis (scarring).
Exposure Routes
Inhalation (L24)
Toxicity Summary
Once in the body, beryllium acts as a hapten and interacts with human leucocyte antigen (HLA) DP presenting cells in the lungs, becoming physically associated with a major histocompatability (MHC) class II molecule. This MHC class II-beryllium-peptide complex is recognized by the T lymphocyte receptor, triggering CD4+ T lymphocyte activation and proliferation. The resulting inflammatory response is a cell-mediated process orchestrated by cytokines and results in the formation of (usually pulmonary) granulomas. Beryllium's toxicity may be controlled by the iron-storage protein ferritin, which sequesters beryllium by binding it and preventing it from interacting with other enzymes. (L25, A37, A91)
Minimum Risk Level
Chronic Oral: 0.002 mg/kg/day (L134)
Carcinogen Classification
1, carcinogenic to humans. (L135)
Non-Human Toxicity Excerpts
/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ A group of 35 female Wistar-derived rats, three months old, received single intratracheal instillations of 50 ug Be as beryllium hydroxide suspended in distilled water, followed 10 months later by a second instillation of 25 ug. A group of 35 controls received a single intratracheal instillation of 2.5 mg chrysotile asbestos. Both materials were suspended in 0.4 mL distilled water, and the instillation was followed by 0.2 mL distilled water. Of the beryllium hydroxide-treated rats sacrificed at 19 months of age, 13/25 had pulmonary tumors (six adenomas and seven adenocarcinomas); one rat had both an epidermoid carcinoma and an adenocarcinoma. The lungs of all of the animals instilled with chrysotile had small and occasionally lar...
Evidence for Carcinogenicity
Beryllium and beryllium compounds are known to be human carcinogens based on sufficient evidence of carcinogenicity from studies in humans. /Beryllium and compounds/
Antidote and Emergency Treatment
Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Monitor cardiac rhythm and treat arrhythmias if necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Beryllium and Related Compou...





